Prospective, randomised, parallel-group, open-label study to evaluate the effectiveness and safety o...
Prospective, randomised, parallel-group, open-label study to evaluate the effectiveness and safety of IMU-838, in combination with oseltamivir, in adults with COVID-19: the IONIC trial protocol
About this item
Full title
Author / Creator
Publisher
London: British Medical Journal Publishing Group
Journal title
Language
English
Formats
Publication information
Publisher
London: British Medical Journal Publishing Group
Subjects
More information
Scope and Contents
Contents
BackgroundGlobally, there is a scarcity of effective treatments for SARS-CoV-2 infections (causing COVID-19). Repurposing existing medications may offer the best hope for treating patients with COVID-19 to curb the pandemic. IMU-838 is a dihydroorotate dehydrogenase inhibitor, which is an effective mechanism for antiviral effects against respirator...
Alternative Titles
Full title
Prospective, randomised, parallel-group, open-label study to evaluate the effectiveness and safety of IMU-838, in combination with oseltamivir, in adults with COVID-19: the IONIC trial protocol
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_22bac54c65a14474b2d65ab18924286d
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_22bac54c65a14474b2d65ab18924286d
Other Identifiers
ISSN
2044-6055
E-ISSN
2044-6055
DOI
10.1136/bmjopen-2021-055205
